StreetInsider.com News Articles

Fortrea and Omico Collaboration to Advance Biomarker-led Oncology Drug Development

Thu, 22 Oct 2026 16:05:00 -0400

Collaboration aims to improve trial planning and expand patient access to biomarker-matched studies in Australia

Highlights

Collaboration aims to accelerate precision oncology research in Australia
Combines Fortrea’s experience in oncology clinical trials with Omico’s Precision Oncology Screening Platform Enabling Clinical Trials (PrOSPeCT) program
Together, Fortrea and Omico offer more efficient investigator site selection and faster patient access by connecting patients with relevant biomarker-driven clinical trials

DURHAM, N.C. and SYDNEY, Oct. 22, 2026 (GLOBE NEWSWIRE) -- Fortrea (Nasdaq: FTRE) (the “Company”), a leading global contract research organization (“CRO”), and Omico, Australia’s leading precision oncology screening

Fortrea and Omico Collaboration to Advance Biomarker-led Oncology Drug Development

Thu, 22 Oct 2026 16:05:00 -0400

Collaboration aims to improve trial planning and expand patient access to biomarker-matched studies in Australia

Highlights

Collaboration aims to accelerate precision oncology research in Australia
Combines Fortrea’s experience in oncology clinical trials with Omico’s Precision Oncology Screening Platform Enabling Clinical Trials (PrOSPeCT) program
Together, Fortrea and Omico offer more efficient investigator site selection and faster patient access by connecting patients with relevant biomarker-driven clinical trials

Fortrea (FTRE) PT Raised to $24 at UBS

Tue, 20 Oct 2026 08:46:18 -0400

UBS analyst Kevin Caliendo raised the price target on Fortrea (NASDAQ: FTRE) to $24.00 (from $22.00) while maintaining a Neutral rating.

Fortrea buys Worldwide Clinical Trials early phase unit for $45M

Mon, 19 Oct 2026 16:05:22 -0400

Fortrea (Nasdaq: FTRE) has completed its acquisition of the Early Phase Services division from Worldwide Clinical Trials in an all-cash transaction valued at approximately $45 million, according to a company statement.

The acquired division includes a 200-bed Good Clinical Practice-compliant clinical research unit in San Antonio, Texas; a 60,000-square-foot Good Laboratory Practice-compliant bioanalytical laboratory in Austin, Texas; and a biospecimen storage facility in Pflugerville, Texas.

The transaction expands Fortrea's early-phase clinical capacity to more than 570 beds globally and adds in-house large and small molecule bioanalytical capabilities. The acquired operations have been integrated into Fortrea's Clinical Pharmacology Services business unit.

Fortrea CEO Anshul

Fortrea Completes Acquisition of the Early Phase Services Division from Worldwide Clinical Trials

Mon, 19 Oct 2026 16:05:00 -0400

Expands Fortrea’s early clinical development network with dedicated bioanalytical capabilities, increased clinical research unit capacity and a more integrated platform for clients

Highlights

Fortrea completes acquisition of the Early Phase Services division from Worldwide Clinical Trials
Adds a 60,000-square-foot GLP-compliant bioanalytical laboratory in Austin, Texas; a 200-bed GCP-compliant clinical pharmacology unit in San Antonio, Texas; and a biospecimen storage facility in Pflugerville, Texas
Expands Fortrea’s early clinical development capacity to more than 570 beds globally and adds dedicated large and small molecule bioanalytical capabilities
Enables more integrated execution of early-phase studies by reducing operational handoffs between clinical and

Fortrea Completes Acquisition of the Early Phase Services Division from Worldwide Clinical Trials

Mon, 19 Oct 2026 16:05:00 -0400

Expands Fortrea’s early clinical development network with dedicated bioanalytical capabilities, increased clinical research unit capacity and a more integrated platform for clients

Highlights

Fortrea completes acquisition of the Early Phase Services division from Worldwide Clinical Trials
Adds a 60,000-square-foot GLP-compliant bioanalytical laboratory in Austin, Texas; a 200-bed GCP-compliant clinical pharmacology unit in San Antonio, Texas; and a biospecimen storage facility in Pflugerville, Texas
Expands Fortrea’s early clinical development capacity to more than 570 beds globally and adds dedicated large and small molecule bioanalytical capabilities
Enables more integrated execution of early-phase studies by reducing operational handoffs between clinical and

Deutsche Bank Upgrades Fortrea (FTRE) to Buy

Thu, 15 Oct 2026 05:57:15 -0400

Deutsche Bank analyst Justin Bowers upgraded Fortrea (NASDAQ: FTRE) from Hold to Buy with a price target of $25.00 (from $20.00).

For an analyst ratings summary and ratings history on Fortrea click here. For more ratings news on Fortrea click here.

Shares of Fortrea closed at $21.34 yesterday.

Deutsche Bank Upgrades Fortrea (FTRE) to Buy

Thu, 15 Oct 2026 05:57:15 -0400

Deutsche Bank analyst Justin Bowers upgraded Fortrea (NASDAQ: FTRE) from Hold to Buy with a price target of $25.00 (from $20.00).

For an analyst ratings summary and ratings history on Fortrea click here. For more ratings news on Fortrea click here.

Shares of Fortrea closed at $21.34 yesterday.

Fortrea shares jump after Barclays upgrade to Overweight

Tue, 06 Oct 2026 09:54:50 -0400

Fortrea Holdings Inc. shares rose about 8.7% in morning trading on Tuesday after Barclays upgraded the contract research organization to Overweight from Equal-Weight and raised its price target to $23.

The stock reached an intraday 52-week high of $23.51 before closing at $22.95.

Barclays analyst Luke Sergott issued the upgrade as part of a broader positive view on the life sciences tools and services sector ahead of third-quarter earnings season. The analyst said he has increased conviction in Fortrea's near-term performance.

The Barclays rating change follows a recent upgrade from UBS, which moved Fortrea to Hold. The stock now has five buy ratings,

Barclays Upgrades Fortrea (FTRE) to Overweight

Tue, 06 Oct 2026 06:11:52 -0400

Barclays analyst Luke Sergott upgraded Fortrea (NASDAQ: FTRE) from Equalweight to Overweight with a price target of $23.00.

For an analyst ratings summary and ratings history on Fortrea click here. For more ratings news on Fortrea click here.

Shares of Fortrea closed at $21.11 yesterday.

Fortrea Announces Date for Third Quarter 2026 Financial Results and Conference Call

Mon, 05 Oct 2026 06:30:00 -0400

DURHAM, N.C., Oct. 05, 2026 (GLOBE NEWSWIRE) -- Fortrea (Nasdaq: FTRE) (the “Company”), a leading global contract research organization (“CRO”), today announced that it will release its third quarter 2026 financial results before the market opens on Thursday, October 29, 2026. The Company will host a conference call at 8:00 a.m. ET on that day to discuss the results.

To participate in the conference call, participants should pre-register via the call registration link. All registrants will receive dial-in details and a unique PIN providing access to the live call. To avoid

Fortrea Announces Date for Third Quarter 2026 Financial Results and Conference Call

Mon, 05 Oct 2026 06:30:00 -0400

Form 8-K Fortrea Holdings Inc. For: Sep 29

Wed, 30 Sep 2026 16:07:00 -0400

si-local-file:///var/storage/secattach/20260930/27128708.html

UBS Starts Fortrea (FTRE) at Neutral

Wed, 30 Sep 2026 05:38:25 -0400

(Updated - September 30, 2026 5:38 AM EDT)

(Updated - September 30, 2026 5:37 AM EDT)

UBS analyst Kevin Caliendo initiates coverage on Fortrea (NASDAQ: FTRE) with a Neutral rating and a price target of $22.00.

The analyst comments: “We initiate coverage of Fortrea at Neutral. While the broader CRO demand environment is improving, FTRE’s bookings recovery has trailed peers, management’s outlook remains measured, and our sponsor survey suggests the company is underrepresented relative to its position as the 6th largest global CRO. We forecast FY27 revenue growth of 2.2% vs consensus at 3.1%, followed by approximately 4%/yr growth beginning in FY28, below

UBS Starts Fortrea (FTRE) at Neutral

Wed, 30 Sep 2026 05:38:25 -0400

(Updated - September 30, 2026 5:38 AM EDT)

(Updated - September 30, 2026 5:37 AM EDT)

UBS analyst Kevin Caliendo initiates coverage on Fortrea (NASDAQ: FTRE) with a Neutral rating and a price target of $22.00.

Fortrea (FTRE) PT Raised to $24 at Baird

Tue, 29 Sep 2026 07:17:48 -0400

Baird analyst Eric Coldwell raised the price target on Fortrea (NASDAQ: FTRE) to $24.00 (from $23.00) while maintaining a Outperform rating.

Form 4 Fortrea Holdings Inc. For: Sep 10 Filed by: Knoblauch Jason Fredrick

Mon, 14 Sep 2026 16:23:00 -0400

si-local-file:///var/storage/secattach/20260914/27058713.html

Form 4 Fortrea Holdings Inc. For: Sep 10 Filed by: Knoblauch Jason Fredrick

Mon, 14 Sep 2026 16:23:00 -0400

si-local-file:///var/storage/secattach/20260914/27058713.html

Form 144/A Fortrea Holdings Inc. Filed by: Mcconnell Jill G.

Fri, 11 Sep 2026 16:13:00 -0400

si-local-file:///var/storage/secattach/20260911/27053018.html

Form 144 Fortrea Holdings Inc. Filed by: Mcconnell Jill G.

Fri, 11 Sep 2026 15:22:00 -0400

si-local-file:///var/storage/secattach/20260911/27052652.html

Fortrea Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

Thu, 10 Sep 2026 17:08:00 -0400

DURHAM, N.C., Sept. 10, 2026 (GLOBE NEWSWIRE) -- Fortrea (Nasdaq: FTRE) (the “Company”), a leading global contract research organization (“CRO”), today announced the granting of an inducement award of restricted stock units (“RSUs”) and performance share units (“PSUs”) on September 10, 2026, to five newly hired employees.

Included in these awards were grants of employment inducement awards to Jason Knoblauch, the Company’s recently appointed Chief Financial Officer, as an inducement material to Mr. Knoblauch becoming a new employee of the Company. The grants were previously approved by the independent members of the Company’s Board

Fortrea Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

Thu, 10 Sep 2026 17:08:00 -0400

Form 4 Fortrea Holdings Inc. For: Sep 08 Filed by: Russell Carrie Elizabeth

Thu, 10 Sep 2026 16:08:00 -0400

si-local-file:///var/storage/secattach/20260910/27048451.html

Form 4 Fortrea Holdings Inc. For: Sep 08 Filed by: Russell Carrie Elizabeth

Thu, 10 Sep 2026 16:08:00 -0400

si-local-file:///var/storage/secattach/20260910/27048451.html

Form 4 Fortrea Holdings Inc. For: Sep 08 Filed by: Morais Mark A.

Thu, 10 Sep 2026 16:06:00 -0400

si-local-file:///var/storage/secattach/20260910/27048408.html